Business
Jaguar Health Appoints Carol Lizak Chief Accounting Officer
SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company
About this update from Jaguar Health, Inc.
[{"type":"text","content":"SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”), a commercial stage pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has promoted Carol Lizak to the role of chief accounting officer for Jaguar. Lizak formerly served as Jaguar’s vice president of finance and corporate controller.Lizak has 20+ years of corporate controllership and financial planning & analysis experience under U.S. GAAP & IFRS. Prior to joining Jaguar, she served as senior director and corporate controller of Zosano Pharma Corporation, as controller of Quantum Secure, Inc., and as executive director, corporate controller of Alexza Pharmaceuticals, Inc. Prior thereto, she spent nine years as corporate controller of a subsidiary of HID Global Corporation. She holds an Executive MBA from Pepperdine Graziadio Business School.“We are very pleased to have appointed Carol to this important role. She was instrumental in supporting our recent successful closing of an underwritten public offering of units for gross proceeds of $16.56 million, and, following the closing of the offering, her effective leadership ensured the timely filing of Jaguar’s 10-Q for the second quarter of 2019. Looking forward, we believe Carol’s extensive financial experience in the life sciences sector will make her a strong addition to our management team as we look to expand our clinical and commercial activities,” Lisa Conte, Jaguar’s president and CEO, commented.About Jaguar Health, Inc.Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.About Mytesi®Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief ...